Americans are beating back death one discovery at a time
By Sandip Shah
Premature deaths from diseases like lung cancer, diabetes, and non-Hodgkin lymphoma have declined over the last quarter century. The reason? Advances in medicine.
Unfortunately, policymakers in Washington seem keen on undermining the incentives needed to develop breakthrough medicines.
Perhaps the most remarkable gains can be found among cancer patients. Age-adjusted death rates from lung cancer dropped 24 percent between 1990 and 2016. For colon cancer, the decrease is nearly 30 percent. And for breast cancer, more than 32 percent.
Early detection has played a major role, but advances in treatment are mostly to thank. They account for 73 percent of the recent rise in cancer survival rates. Since 2006, the Food and Drug Administration has approved more than 110 new oncology drugs.
Or look at ischemic heart disease. The condition is still the leading cause of premature death among Americans. But the number of “years of life lost” from this condition declined by more than 50 percent between 1990 and 2016.
A class of drugs known as statins reduced the risk of death from coronary heart disease in men by 28 percent over two decades.
Many statins are now available generically and will provide cardiovascular disease treatment for generations to come.
Despite these hopeful trends, the challenges posed by chronic illness remain daunting. Ischemic heart disease, lung cancer, and colon cancer are still among the top five causes of early death in the United States.
Overcoming these health crises will require a new generation of innovative treatments.
There are more than 200 new medicines for heart disease and stroke currently under development. The pipeline for cancer treatments includes more than 800 potential drugs.
Unfortunately, there is no guarantee that the next medical breakthrough is just around the corner. That’s why policies that deter research are so dangerous.
Some have started calling for the government to regulate prices. But without the ability to set their own prices, researchers might decide that the financial risks involved in developing new medicines are too high.
It takes $2.6 billion and around 10 years to create just one commercially available drug. What makes this massive up-front cost acceptable to drug firms and investors is the expectation that should a medicine become successful, they can recoup some of this investment.
If the government is put in charge of pricing drugs, investing in pharmaceutical research would become even riskier. Investors would flee to safer industries. Funding for much needed medical advances would dry up.
In other words, the next medical breakthrough could be obstructed by short-sighted political rationale. This would deprive millions of people access to life-saving therapies for decades to come.
America has made encouraging progress in battling the most serious public-health threats of the last few decades. It owes much of those gains to new treatments that were unimaginable just a few years ago. Now is no time to undermine the source of that innovation with misguided government policies.
Sandip Shah is the founder and president of Market Access Solutions, a global market access consultancy, where he develops strategies to optimize patient access to life-changing therapies.
The viewpoints expressed above are those of the author and do not necessarily reflect those of The Independent.
How to submit an article, guest opinion piece, or letter to the editor to The Independent
Do you have something to say? Want your voice to be heard by thousands of readers? Send The Independent your letter to the editor or guest opinion piece. All submissions will be considered for publication by our editorial staff. If your letter or editorial is accepted, it will run on suindependent.com, and we’ll promote it through all of our social media channels. We may even decide to include it in our monthly print edition. Just follow our simple submission guidelines and make your voice heard:
—Submissions should be between 300 and 1,500 words.
—Submissions must be sent to editor@infowest.com as a .doc, .docx, .txt, or .rtf file.
—The subject line of the email containing your submission should read “Letter to the editor.”
—Attach your name to both the email and the document file (we don’t run anonymous letters).
—If you have a photo or image you’d like us to use and it’s in .jpg format, at least 1200 X 754 pixels large, and your intellectual property (you own the copyright), feel free to attach it as well, though we reserve the right to choose a different image.
—If you are on Twitter and would like a shout-out when your piece or letter is published, include that in your correspondence and we’ll give you a mention at the time of publication.
Articles related to “Americans are beating back death one discovery at a time”
Hamburgers and coprophagia: There’s poop in your meat, y’all
